The FY21 Defense Appropriations Act provides funding to the Department of Defense Breast Cancer Research Program to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for service members, veterans, and the general public.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
